# Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer

> **NCT02355119** · PHASE3 · UNKNOWN · sponsor: **Azienda Ospedaliero, Universitaria Pisana** · enrollment: 310 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** FOLFOXIRI
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02355119
- **Lead sponsor:** Azienda Ospedaliero, Universitaria Pisana
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2017-12
- **Final completion:** 2018-12
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2015-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02355119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02355119, "Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02355119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*